Cul4B is a novel prognostic marker in cholangiocarcinoma

Li,Pengyu; Zhang,Lili; Yang,Muyi; Qi,Mei; Jin,Xing; Han,Bo

doi:10.3892/ol.2017.6297

Cul4B is a novel prognostic marker in cholangiocarcinoma

Authors:
- Pengyu Li
- Lili Zhang
- Muyi Yang
- Mei Qi
- Xing Jin
- Bo Han
View Affiliations

Affiliations: Department of Emergency Surgery, Shandong University Qilu Hospital, Jinan, Shandong 250012, P.R. China, Department of Pathology, Shandong University Medical School, Jinan, Shandong 250012, P.R. China, Department of Vascular Surgery, Shandong Provincial Hospital, Jinan, Shandong 250012, P.R. China
Published online on: June 1, 2017 https://doi.org/10.3892/ol.2017.6297
Pages: 1265-1274
Copyright: © Li et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Cullin 4B (Cul4B), a scaffold protein that assembles the ubiquitin ligase complex, is involved in a wide variety of physiological and developmental processes, such as cell cycle progression, DNA damage response and gene expression regulation. Cul4B is overexpressed in various solid tumors. However, the prognostic value and role of Cul4B in cholangiocarcinoma (CCA) is largely unknown. The present study demonstrated that Cul4B was overexpressed in 21 (26.6%) of 79 patients with intrahepatic CCA, and in 40 (28.6%) of 140 patients with extrahepatic CCA (EHCC). Kaplan‑Meier survival analysis suggested that Cul4B expression is an unfavorable prognostic factor in EHCC patients. Notably, Cul4B and epidermal growth factor receptor expression define a subset of CCA patients with poor prognosis. In vitro data indicated that Cul4B promotes the proliferation, migration and invasion of CCA cells. Furthermore, Cul4B expression promotes the epithelial‑mesenchymal transition (EMT) process in CCA cells. Finally, Cul4B repressed the expression of the tumor suppressor genes P16 and phosphatase and tensin homolog. Collectively, the results of the present study revealed an important role of Cul4B in CCA with respect to initiating EMT. Cul4B expression may serve as a prognostic marker for patients with EHCC.

View Figures

View References

1	Blechacz B, Komuta M, Roskams T and Gores GJ: Clinical diagnosis and staging of cholangiocarcinoma. Nat Rev Gastroenterol Hepatol. 8:512–522. 2011. View Article : Google Scholar : PubMed/NCBI
2	Patel T: Cholangiocarcinoma-controversies and challenges. Nat Rev Gastroenterol Hepatol. 8:189–200. 2011. View Article : Google Scholar : PubMed/NCBI
3	Malhi H and Gores GJ: Cholangiocarcinoma: Modern advances in understanding a deadly old disease. J Hepatol. 45:856–867. 2006. View Article : Google Scholar : PubMed/NCBI
4	Hezel AF and Zhu AX: Systemic therapy for biliary tract cancers. Oncologist. 13:415–423. 2008. View Article : Google Scholar : PubMed/NCBI
5	Briggs CD, Neal CP, Mann CD, Steward WP, Manson MM and Berry DP: Prognostic molecular markers in cholangiocarcinoma: A systematic review. Eur J Cancer. 45:33–47. 2009. View Article : Google Scholar : PubMed/NCBI
6	Petroski MD and Deshaies RJ: Function and regulation of cullin-RING ubiquitin ligases. Nat Rev Mol Cell Biol. 6:9–20. 2005. View Article : Google Scholar : PubMed/NCBI
7	Sarikas A, Hartmann T and Pan ZQ: The cullin protein family. Genome Biol. 12:2202011. View Article : Google Scholar : PubMed/NCBI
8	Zou Y, Mi J, Cui J, Lu D, Zhang X, Guo C, Gao G, Liu Q, Chen B, Shao C and Gong Y: Characterization of nuclear localization signal in the N terminus of CUL4B and its essential role in cyclin E degradation and cell cycle progression. J Biol Chem. 284:33320–33332. 2009. View Article : Google Scholar : PubMed/NCBI
9	Jiang T, Tang HM, Wu ZH, Chen J, Lu S, Zhou CZ, Yan DW and Peng ZH: Cullin 4B is a novel prognostic marker that correlates with colon cancer progression and pathogenesis. Med Oncol. 30:5342013. View Article : Google Scholar : PubMed/NCBI
10	Yuan J, Han B, Hu H, Qian Y, Liu Z, Wei Z, Liang X, Jiang B, Shao C and Gong Y: CUL4B activates Wnt/β-catenin signalling in hepatocellular carcinoma by repressing Wnt antagonists. J Pathol. 235:784–795. 2015. View Article : Google Scholar : PubMed/NCBI
11	Hu H, Yang Y, Ji Q, Zhao W, Jiang B, Liu R, Yuan J, Liu Q, Li X, Zou Y, et al: CRL4B catalyzes H2AK119 monoubiquitination and coordinates with PRC2 to promote tumorigenesis. Cancer Cell. 22:781–795. 2012. View Article : Google Scholar : PubMed/NCBI
12	Nauseef JT and Henry MD: Epithelial-to-mesenchymal transition in prostate cancer: Paradigm or puzzle? Nat Rev Urol. 8:428–439. 2011. View Article : Google Scholar : PubMed/NCBI
13	Thompson EW, Newgreen DF and Tarin D: Carcinoma invasion and metastasis: A role for epithelial-mesenchymal transition? Cancer Res. 65:5991–5995. 2015. View Article : Google Scholar
14	Kong D, Banerjee S, Ahmad A, Li Y, Wang Z, Sethi S and Sarkar FH: Epithelial to mesenchymal transition is mechanistically linked with stem cell signatures in prostate cancer cells. PLoS One. 5:e124452010. View Article : Google Scholar : PubMed/NCBI
15	Wang L, Zhang J, Yang X, Chang YW, Qi M, Zhou Z, Zhang J and Han B: SOX4 is associated with poor prognosis in prostate cancer and promotes epithelial-mesenchymal transition in vitro. Prostate Cancer Prostatic Dis. 16:301–307. 2013. View Article : Google Scholar : PubMed/NCBI
16	Yang Y, Liu R, Qiu R, Zheng Y, Huang W, Hu H, Ji Q, He H, Shang Y, Gong Y and Wang Y: CRL4B promotes tumorigenesis by coordinating with SUV39H1/HP1/DNMT3A in DNA methylation-based epigenetic silencing. Oncogene. 34:104–118. 2015. View Article : Google Scholar : PubMed/NCBI
17	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(−Delta Delta C(T)) method. Method. 25:402–408. 2011. View Article : Google Scholar
18	Edge SB and Compton CC: The American Joint Committee on Cancer: The 7th edition of the AJCC cancer staging manual and the future of TNM. Ann Surg Oncol. 17:1471–1474. 2010. View Article : Google Scholar : PubMed/NCBI
19	Lee J and Zhou P: Pathogenic role of the CRL4 ubiquitin ligase in human disease. Front Oncol. 2:212012. View Article : Google Scholar : PubMed/NCBI
20	Mok MT and Cheng AS: CUL4B: A novel epigenetic driver in Wnt/β-catenin-dependent hepatocarcinogenesis. J Pathol. 236:1–4. 2015. View Article : Google Scholar : PubMed/NCBI
21	Beroukhim R, Mermel CH, Porter D, Wei G, Raychaudhuri S, Donovan J, Barretina J, Boehm JS, Dobson J, Urashima M, et al: The landscape of somatic copy-number alteration across human cancers. Nature. 463:899–905. 2010. View Article : Google Scholar : PubMed/NCBI
22	Jarnagin WR, Klimstra DS, Hezel M, Gonen M, Fong Y, Roggin K, Cymes K, DeMatteo RP, D'Angelica M, Blumgart LH and Singh B: Differential cell cycle-regulatory protein expression in biliary tract adenocarcinoma: Correlation with anatomic site, pathologic variables, and clinical outcome. J Clin Oncol. 24:1152–1160. 2006. View Article : Google Scholar : PubMed/NCBI
23	Zhang H, Berezov A, Wang Q, Zhang G, Drebin J, Murali R and Greene MI: ErbB receptors: From oncogenes to targeted cancer therapies. J Clin Invest. 117:2051–2058. 2007. View Article : Google Scholar : PubMed/NCBI
24	Wang Y, Zhang P, Liu Z, Wang Q, Wen M, Wang Y, Yuan H, Mao JH and Wei G: CUL4A overexpression enhances lung tumor growth and sensitizes lung cancer cells to erlotinib via transcriptional regulation of EGFR. Mol Cancer. 13:2522014. View Article : Google Scholar : PubMed/NCBI